Please login to the form below

Not currently logged in
Email:
Password:

RMS

This page shows the latest RMS news and features for those working in and with pharma, biotech and healthcare.

Novartis gains EU approval for relapsing MS drug Kesimpta

Novartis gains EU approval for relapsing MS drug Kesimpta

Also recently entering the RMS market is Johnson &Johnson’s (J&J) Ponvory (ponesimod), which scored approval in the US in March. ... Last week, the CHMP issued a positive opinion for Ponvory in the RMS indication, moving it closer towards EU approval.

Latest news

  • J&J’s multiple sclerosis therapy Ponvory moves closer to EU approval J&J’s multiple sclerosis therapy Ponvory moves closer to EU approval

    J&J's pharma division Janssen announced today that the  CHMP recommends approval of the marketing authorisation for Ponvory (ponesimod), for the treatment of adult patients with relapsing MS (RMS), with ... added. Last week, the US Food and Drug

  • Novartis builds its case for novel MS treatment ofatumumab Novartis builds its case for novel MS treatment ofatumumab

    The ASCLEPIOS I and II trials evaluated a subcutaneous injection of ofatumumab compared to Sanofi’s once-daily oral Aubagio (teriflunomide) pill in adults with relapsing multiple sclerosis (RMS). ... ASCLEPIOS I and II demonstrate the efficacy and

  • Merck takes evobrutinib for MS into phase 3, on mixed data Merck takes evobrutinib for MS into phase 3, on mixed data

    The principal investigator in the EVOLUTION RMS 2 trial – Xavier Montalban of the University of Toronto and St. ... Even with the most effective therapies for RMS, more than 50% of patients experience clinical or subclinical disease activity,” he said

  • Novartis scores promising phase 3 MS study Novartis scores promising phase 3 MS study

    Ofatumumab, if approved, could be a highly attractive treatment option for a broad RMS patient population, including early MS,” said John Tsai, head global drug development and chief medical officer, Novartis.

  • Roche's MS drug Ocrevus awarded priority review by FDA Roche's MS drug Ocrevus awarded priority review by FDA

    Roche is seeking a licence for the drug to treat both forms of MS - relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) -which respond poorly to current therapies. ... In the Opera I and II clinical trials for RMS,

More from news
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?
The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.
Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....

Infographics